Tenet Healthcare reports Q2 net income of $826M, raises FY guidance, authorizes $2B buyback

Filed July 23, 2026 · Period ending July 23, 2026 · ~1 min read

Key Changes

• high

  Q2 2026 net income $826M ($9.84/share) vs. $288M ($3.14/share) in Q2 2025; raised FY 2026 Adjusted EBITDA guidance to $4.83–$5.03B (up $295M at midpoint) and Adjusted Free Cash Flow to $2.725–$3.025B (up $225M).

  Exhibit 99.1 view on EDGAR →
• high

  Board authorized $2.0B increase to share repurchase program, bringing total remaining authorization to $2.13B as of July 23, 2026; repurchased 5.68M shares for $1.042B in Q2 2026.

  Exhibit 99.1 view on EDGAR →
• high

  Q2 2026 Consolidated Adjusted EBITDA rose 16.3% to $1.304B with 23.2% margin; Hospital segment margin expanded to 18.0% from 15.6% in Q2 2025 despite payer mix headwinds.

  Exhibit 99.1 view on EDGAR →